Mark Cuban on PBMs, TrumpRx, and Disrupting Healthcare Costs

Mark Cuban's Cost Plus Drugs: Growth and Impact

• 🚀 Launched in 2022, Cost Plus Drugs has exceeded expectations, helping millions through word-of-mouth with no advertising.
• 💡 The company has seen significant growth and demand for partnerships, particularly with transparent PBMs.
• 🎯 Cost Plus Drugs aims to lower prices by increasing volume and passing savings directly to patients.

Critiquing Pharmacy Benefit Managers (PBMs)

• ⚠️ Cuban asserts that large PBMs are overcharging companies and misleading them about transparency.
• 🔍 He highlights that audits of PBM claims consistently reveal overpayments by companies.
• 💰 PBMs allegedly use rebates to keep CEOs and CFOs dependent, increasing prices when alternatives like Cost Plus Drugs are considered.
• 🚫 PBMs are accused of blocking efforts to integrate Cost Plus Drugs into their networks, even when Cost Plus offers lower prices.

The PBM-Wholesaler Collusion and Drug Pricing

• 🧩 The current drug pricing system is described as a complex chain involving manufacturers, wholesalers, PBMs, and pharmacies, with PBMs and wholesalers accused of collusion.
• 📉 The list price (WAC) is artificially high, allowing PBMs to generate substantial rebate revenue, which obscures the true net cost.
• ⚡ For high-demand drugs like GLP-1s, the inflated WAC and rebate system prevent lower net prices, even if manufacturers could offer them.
• 🏥 PBMs are criticized for auctioning formulary access rather than negotiating prices, leading to decisions that may not be in the best interest of patients or employers.

Proposed Solutions and Future Outlook

• 🤝 Cuban is advocating for legislation in several states to allow patients to apply cash drug purchases to their insurance deductibles.
• 💡 He supports initiatives like TrumpRx as a step towards reducing prescription costs, though he views them as superficial without addressing core PBM issues.
• 🧩 True disruption requires disaggregating the PBM-wholesaler system by either requiring net pricing from manufacturers or allowing entities to create their own formularies.
• 🎯 Cuban believes the healthcare industry is ripe for disruption due to its complexity and the arbitrage opportunities present, and he is committed to driving change.